Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Atienza (Madrid, Spain), N. Benjamin (Boston, United States of America), M. Schroeder (Brentford, United Kingdom), L. Vallejo-Aparicio (Madrid, Spain), C. Biswas (Bengaluru, India), D. Shah (New York, United States of America), A. Ismaila (Collegeville, United States of America). Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain. 3155

Member's Comments

No comment yet.

Related content which might interest you: Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002 Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Cost burden in COPD patients initiating ICS vs. non-ICS maintenance regimens Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Evaluation of adherence of patients with asthma to treatment by single combination inhaler Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 De-implementing inappropriate inhaled steroids use in Dutch COPD patients in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Asthma-related resource use and costs for patients prescribed inhaled corticosteroids compared to leukotriene modifiers in clinical practice Source: Annual Congress 2010 - Management of airway disease Year: 2010 Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Influence of treatment by single combined inhaler on adherence of patients with asthma Source: Annual Congress 2009 - Respiratory physiology Year: 2009 Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: a prescribing claims study of 2823 patients using a CFC - pMDI and a breath-actuated device Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001 Reduced healthcare resource utilization in asthma patients treated with omalizumab in the clinical practice in Spain Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Budesonide/formoterol for the treatment of COPD exacerbations in the primary healthcare setting Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The drug costs associated with COPD prescription medicine in Denmark Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Economic outcomes in the United States of treating COPD with inhaled corticosteroids and long-acting β-agonists in a managed care setting Source: Eur Respir J 2003; 22: Suppl. 45, 216s Year: 2003